Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo
Important Safety Information | Patient Site
Prescribing Information
    • Why NovoSeven® RT?
    • Pharmacology
    • Congenital Hemophilia A & B with Inhibitors
    • Breakthrough Bleeds
    • Acquired Hemophilia
    • Congenital Factor VII Deficiency
    • Glanzmann's Thrombasthenia
    • Hospital Overview
    • Clinical Pathway for Emergent Bleeds
    • Clinical Pathway for Acquired Hemophilia
    • Hospital Pharmacies
    • Dosing Calculator
    • Quick Reference
    • Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo

Indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and in adults with acquired hemophilia.

Prescribing Information
Important Safety Information | Patient Site

Works at the site of injury1

NovoSeven® RT is recombinant Factor VIIa. It can support thrombin generation for patients with congenital hemophilia A or B with inhibitors.1,2

Works at the site of injury1

NovoSeven® RT is a recombinant Factor VIIa. It can support thrombin generation for patients with congenital hemophilia A or B with inhibitors.1,2

Works at the site of injury1

NovoSeven® RT is a recombinant Factor VIIa. It can support thrombin generation for patients with congenital hemophilia A or B with inhibitors.1,2

Prescribing Information | Important Safety Information
NovoSeven® RT Mechanism of Action in CHwI
(7:19)
NovoSeven® RT Mechanism of Action in CHwI
See how NovoSeven® RT works at the site of vascular injury, when used in the treatment of congenital hemophilia with inhibitors (CHwI).
Watch video
Prescribing Information | Important Safety Information

NovoSeven® RT resolves bleeds in CHwI by allowing the formation of a stable hemostatic plug

NovoSeven® RT enters the bloodstream and targets the site of injury
Step 1

Targeting

NovoSeven® RT enters the bloodstream and targets the site of injury. It can support thrombin generation for patients with congenital hemophilia (FVIII or FIX deficiency) who have inhibitors to replacement factor.1,2

NovoSeven® RT binds directly to activated platelets, activating FX to produce FXa
Step 2

Activation

NovoSeven® RT binds directly to activated platelets, activating FX to produce FXa.1,2 FXa complexes with other factors to convert prothrombin to thrombin.1

The burst of thrombin leads to the formation of fibrin, which is the foundation of a stable clot
Step 3

Clot formation

The burst of thrombin leads to the formation of fibrin, which is the foundation of a stable clot.1

NovoSeven® RT resolves the bleed by allowing the formation of a stable hemostatic plug
Step 4

Bleed resolution

NovoSeven® RT resolves the bleed by allowing the formation of a stable hemostatic plug.1

A recombinant bypassing agent not made from human serum or human proteins1

NovoSeven® RT is manufactured in cell lines considered to be free of viruses, and undergoes additional steps to ensure safety and purity. Recombinant factor products minimize the possibility of viral contamination.1,3

Review recombinant safety info
HCP and patient

Approved for bleed management and surgical use in patients with CHwI.

See the clinical data
HCP talking with patient in the hospital

Learn about a rare and serious condition.

Understanding acquired hemophilia

Selected Important Safety Information for NovoSeven® RT

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.

References

  1. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020.
  2. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost. 2001; 85(6):958-965.
  3. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders, #263. New York, NY: National Hemophilia Foundation; 2020.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved. US23NSVN00057 October 2023

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials